Bicalutamide is a medication that blocks the effects of male sex hormones (androgens) on the body. It is FDA-approved to treat metastatic prostate cancer, meaning cancer that has spread beyond the prostate, and it is used in combination with another type of hormone-suppressing drug rather than on its own. Beyond its approved use, it is sometimes prescribed off-label for conditions driven by androgen activity, including severe hirsutism in women.
How Bicalutamide Works
Bicalutamide works by attaching to androgen receptors, the docking sites on cells where testosterone and similar hormones normally bind to trigger growth signals. By occupying those receptors, the drug prevents androgens from delivering their message, effectively starving androgen-sensitive tissues of hormonal stimulation. It does not lower testosterone levels on its own. In fact, when used alone, it can cause testosterone and estrogen levels to rise because the body senses that its androgen signals are being blocked and tries to compensate.
This is why bicalutamide is paired with a second drug for prostate cancer treatment. That companion drug, called an LHRH agonist, works upstream by shutting down the hormonal signal that tells the body to produce testosterone in the first place. Together, the two medications create a more complete androgen blockade: one cuts production, the other blocks whatever testosterone still reaches the cancer cells.
Its Role in Prostate Cancer
Bicalutamide is approved at a daily dose of 50 mg, taken once a day alongside an LHRH agonist, for metastatic prostate cancer. Treatment with both drugs is started at the same time. The tablet can be taken in the morning or evening, with or without food, ideally at a consistent time each day.
A higher dose of 150 mg daily was studied as a standalone alternative to surgical castration in men with locally advanced or metastatic disease, but it is not approved. In two large trials comparing the 150 mg dose to castration, safety monitoring boards found that men on the higher dose had a 25% to 31% higher risk of death compared to those who underwent castration. A separate analysis in men with localized prostate cancer under watchful waiting also showed a trend toward worse survival with the 150 mg dose. These findings firmly established that the drug works best as part of a combination, not as a replacement for testosterone suppression.
Off-Label Use for Severe Hirsutism
Because bicalutamide blocks androgen receptors throughout the body, it has drawn interest for treating androgen-driven conditions in women, particularly severe excess hair growth (hirsutism) associated with polycystic ovary syndrome (PCOS). A randomized controlled trial published in the Journal of Clinical Endocrinology & Metabolism tested 50 mg of bicalutamide daily combined with an oral contraceptive pill against the contraceptive pill alone in 70 women with classic PCOS and severe hirsutism.
After 12 months, women taking the combination saw a 79% reduction in a standardized hair growth score, compared to a 55% reduction in women on the contraceptive pill alone. The combination also worked faster: at six months, the bicalutamide group already showed a 67% reduction, while the contraceptive-only group had not yet reached a statistically significant change. The treatment was generally well tolerated, though the bicalutamide group did see increases in total cholesterol and LDL cholesterol that the other group did not. Only one participant dropped out due to weight gain.
Oral contraceptives are essential when bicalutamide is used in women of reproductive age because the drug could cause harm to a developing male fetus by interfering with normal androgen-driven development.
Use in Feminizing Hormone Therapy
Some clinicians have used bicalutamide off-label as part of feminizing hormone therapy for transgender women, where its ability to block androgen receptors could help reduce masculine features like body hair and male-pattern skin oiliness. However, major guidelines are cautious. UCSF’s Transgender Care guidelines note that bicalutamide carries a small but not fully understood risk of serious liver problems, including rare cases of severe hepatitis. While that risk may be acceptable in the context of prostate cancer, the guidelines point out it is harder to justify for gender-affirming care, especially when other anti-androgen options exist. No robust clinical data currently supports a recommended dose or protocol for this use.
Breast Enlargement and Breast Pain
The most common side effects of bicalutamide are breast tissue growth (gynecomastia) and breast tenderness. In large clinical trials, these occurred in roughly 68% and 74% of patients, respectively, with most cases developing within the first six to nine months. These effects happen because the drug’s androgen blockade shifts the hormonal balance toward estrogen, which stimulates breast tissue.
For prostate cancer patients, this can be distressing. Several approaches are used to manage or prevent it. A low-dose estrogen-blocking medication taken daily has been shown to be effective at both preventing and treating the condition. A single session of targeted radiation to the chest area before or shortly after starting treatment is another option with comparable results. In some cases, surgical removal of the excess tissue is considered if other methods fail.
Liver Safety
Bicalutamide is processed by the liver, and in roughly 1% of patients in clinical trials, it caused significant liver enzyme elevations or hepatitis serious enough to require stopping the drug. Rare but severe cases of liver failure have been reported. Because of this, liver function blood tests are recommended before starting the medication, at regular intervals during the first four months, and periodically after that. If you notice symptoms like unusual fatigue, dark urine, yellowing of the skin or eyes, or persistent nausea, these can be signs of liver stress that need prompt evaluation.